Former Names FVB/N-Tg(teto-Kras2)12Hev (Changed: 15-DEC-04 ) Type Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Species laboratory mouse Donating Investigator Dr. Harold E. Varmus, Memorial Sloan-Kettering Cancer Center Description
Mice that are homozygous for the transgene are viable and fertile. These transgenic mice express activated rat Kras (Kras4bG12D) under the regulation of a tetracycline-responsive promoter element (TRE; tetO). When these mice are mated to strains containing transgenes encoding either rtTA (reverse tetracycline trans-activator protein) or tTA (the tetracycline trans-activator), activated Kras expression in the bitransgenic animals can be induced by administration or withdrawl, respectively, of the tetracycline analog, doxycycline. This strain represents an effective tool for generating tissue specific mutants that would be useful models for studying oncogene activation in human carcinogenesis.Development
A transgenic construct containing the mutant gene (Kras4bG12D) under the regulation of a tetracycline-responsive promoter element (TRE; tetO), the mp-1 intron and polyadenylation site sequence, and a minimal CMV promoter was injected into FVB/N blastocysts.
| Control | ||
|---|---|---|
| 001800 FVB/NJ | ||
| Considerations for Choosing Controls | ||
Strains carrying other alleles of CMV
017456 B6(C)-Tg(CAG-mCherry,-GAL4)769Gsn/J 017457 B6(C)-Tg(CAG-mCherry,-GAL4)774Gsn/J 021469 B6(D2)-Tg(CAG-GFP,-Uprt)985Cdoe/J 018439 B6.129S6-Tg(CAG-Bgeo,-SMN2)E9Dscd/J 006054 B6.C-Tg(CMV-cre)1Cgn/J 016197 B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J 018021 B6.Cg-Tg(CAG-Tfb1m)AGsha/J 016882 B6.Cg-Tg(CMV-CASP3)14Edge/J 016908 B6.Cg-Tg(CMV-CASP3)17Edge/J 008300 B6.Cg-Tg(CMV-Klc1)73Gsn/J 008301 B6.Cg-Tg(CMV-Klc1)90Gsn/J 007237 B6.Cg-Tg(CMV-Serpine1)1Dgi/J 018056 B6.FVB-Tg(CAG-boNT/B,-EGFP)U75-56Fwp/J 017524 B6;129-Tg(CMV-Bgeo,-WGA,-ALPP)1Mgmj/J 014605 B6;129S-Tg(CMV-BBS1)6Vcs/J 017954 B6;C-Tg(CAG-Epha4/Efna5,-mCherry)1Slp/J 016532 B6N.FVB(Cg)-Tg(CAG-rtTA3)4288Slowe/J 003465 BALB/c-Tg(CMV-cre)1Cgn/J 010545 C.FVB-Tg(CAG-luc,-GFP)L2G85Chco/FathJ 014564 C57BL/6-Tg(CMV-Tsc2*)1Arbi/KlanJ 006362 C57BL/6J-Tg(CMV-Cox8a/EYFP)17J/J 010548 D1.FVB(Cg)-Tg(CAG-luc,-GFP)L2G85Chco/FathJ 018543 FVB-Tg(CAG-cat,-Twist1)1Dbsp/J 008450 FVB-Tg(CAG-luc,-GFP)L2G85Chco/J 006439 FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J 018393 FVB/N-Tg(CAG-EGFP,TGFB1*)C8Akul/J 004644 NOD.Cg Prkdcscid-Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy/YgyJ 013062 NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ 011066 NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy/YgyJGckRolyJ 010542 NOD.FVB-Tg(CAG-luc,-GFP)L2G85Chco/FathJ 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 013753 STOCK Tg(CAG-KikGR)33Hadj/J 013754 STOCK Tg(CAG-KikGR)75Hadj/J 019082 STOCK Tg(CMV-GFP,-BBS4)4T25Vcs/J 002471 STOCK Tg(hCMV-cre)140Sau/J 014093 STOCK Tg(tetO-CHRM3*)1Blr/J View Strains carrying other alleles of CMV (36 strains)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Cancer Research
Increased Tumor Incidence
Adenomas
Adenomas: lung, induced
Other Tissues/Organs
Other Tissues/Organs: lung, induced
Research Tools
Tet Expression Systems
tTA/rtTA Responsive Strains
| Allele Symbol | Tg(tetO-Kras2)12Hev | ||
|---|---|---|---|
| Allele Name | transgene insertion 12, Harold E Varmus | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | K-Ras4bG12D responder; K-Ras4bG12D responder; K-ras4bG12D; K-rasG12D-5; KE; TOR; TRE-KrasG12D; Tet-op-K-RasG12D; Tet-op-K-ras; TetO-KrasG12D; tre-Kras; | ||
| Mutation Made By | Dr. Harold Varmus, Memorial Sloan-Kettering Cancer Center | ||
| Strain of Origin | FVB/N | ||
| Expressed Gene | Kras, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, rat | ||
| Promoter | CMV, cytomegalovirus, human | ||
| General Note | Homozygous transgenic mice are viable and fertile. In conjunction with a second transgene encoding either rtTA (reverse tetracycline trans-activator protein) or tTA (the tetracycline trans-activator), mice carrying Tg(tetO-Kras2)12Hev show tissue-specific expression of the mutated K-ras transgene that may be induced or suppressed by administration of the tetracycline analog, doxycycline. Cessation or initiation of doxycycline treatment in bitransgenic strains containing, respectively, rtTA or tTA, will result in a rapid decrease of expression of the transgene. | ||
| Molecular Note | The transgene expresses the mutant gene Kras4bG12D, under the control of a tetracycline-responsive promoter element (tTA), mp-1 intron polyadenylation site sequence, and a minimal CMV promoter. [MGI Ref ID J:73468] | ||
Genotyping Protocols
Tg(tetO-Kras2)12Hev, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Fisher GH; Wellen SL; Klimstra D; Lenczowski JM; Tichelaar JW; Lizak MJ; Whitsett JA; Koretsky A; Varmus HE. 2001. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15(24):3249-62. [PubMed: 11751631] [MGI Ref ID J:73468]
Tg(tetO-Kras2)12Hev relatedChow HY; Jubb AM; Koch JN; Jaffer ZM; Stepanova D; Campbell DA; Duron SG; O'Farrell M; Cai KQ; Klein-Szanto AJ; Gutkind JS; Hoeflich KP; Chernoff J. 2012. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res 72(22):5966-75. [PubMed: 22983922] [MGI Ref ID J:192901]
Collins MA; Bednar F; Zhang Y; Brisset JC; Galban S; Galban CJ; Rakshit S; Flannagan KS; Adsay NV; Pasca di Magliano M. 2012. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122(2):639-53. [PubMed: 22232209] [MGI Ref ID J:184378]
Collins MA; Brisset JC; Zhang Y; Bednar F; Pierre J; Heist KA; Galban CJ; Galban S; di Magliano MP. 2012. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One 7(12):e49707. [PubMed: 23226501] [MGI Ref ID J:195686]
Duran A; Linares JF; Galvez AS; Wikenheiser K; Flores JM; Diaz-Meco MT; Moscat J. 2008. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 13(4):343-54. [PubMed: 18394557] [MGI Ref ID J:136133]
Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; Garcia-Echeverria C; Weissleder R; Mahmood U; Cantley LC; Wong KK. 2008. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12):1351-6. [PubMed: 19029981] [MGI Ref ID J:142254]
Galvez AS; Duran A; Linares JF; Pathrose P; Castilla EA; Abu-Baker S; Leitges M; Diaz-Meco MT; Moscat J. 2009. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Mol Cell Biol 29(1):104-15. [PubMed: 18955501] [MGI Ref ID J:144073]
Hsu TI; Wang MC; Chen SY; Yeh YM; Su WC; Chang WC; Hung JJ. 2012. Sp1 expression regulates lung tumor progression. Oncogene 31(35):3973-88. [PubMed: 22158040] [MGI Ref ID J:187868]
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Janne PA; Johnson BE; Chin L; Wong KK. 2007. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 67(10):4933-9. [PubMed: 17510423] [MGI Ref ID J:121738]
Kim CF; Jackson EL; Kirsch DG; Grimm J; Shaw AT; Lane K; Kissil J; Olive KP; Sweet-Cordero A; Weissleder R; Jacks T. 2005. Mouse models of human non-small-cell lung cancer: raising the bar. Cold Spring Harb Symp Quant Biol 70:241-50. [PubMed: 16869760] [MGI Ref ID J:116813]
Konstantinidou G; Bey EA; Rabellino A; Schuster K; Maira MS; Gazdar AF; Amici A; Boothman DA; Scaglioni PP. 2009. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 69(19):7644-52. [PubMed: 19789349] [MGI Ref ID J:153586]
Nielsen CH; Kimura RH; Withofs N; Tran PT; Miao Z; Cochran JR; Cheng Z; Felsher D; Kjaer A; Willmann JK; Gambhir SS. 2010. PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. Cancer Res 70(22):9022-30. [PubMed: 21062977] [MGI Ref ID J:166856]
Podsypanina K; Politi K; Beverly LJ; Varmus HE. 2008. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci U S A 105(13):5242-7. [PubMed: 18356293] [MGI Ref ID J:133578]
Politi K; Fan PD; Shen R; Zakowski M; Varmus H. 2010. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech 3(1-2):111-9. [PubMed: 20007486] [MGI Ref ID J:157671]
Raimondi AR; Vitale-Cross L; Amornphimoltham P; Gutkind JS; Molinolo A. 2006. Rapid development of salivary gland carcinomas upon conditional expression of K-ras driven by the cytokeratin 5 promoter. Am J Pathol 168(5):1654-65. [PubMed: 16651631] [MGI Ref ID J:108579]
Redente EF; Dwyer-Nield LD; Merrick DT; Raina K; Agarwal R; Pao W; Rice PL; Shroyer KR; Malkinson AM. 2010. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 176(6):2972-85. [PubMed: 20431028] [MGI Ref ID J:161329]
Sotillo R; Schvartzman JM; Socci ND; Benezra R. 2010. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 464(7287):436-40. [PubMed: 20173739] [MGI Ref ID J:158125]
Sullivan JP; Spinola M; Dodge M; Raso MG; Behrens C; Gao B; Schuster K; Shao C; Larsen JE; Sullivan LA; Honorio S; Xie Y; Scaglioni PP; DiMaio JM; Gazdar AF; Shay JW; Wistuba II; Minna JD. 2010. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70(23):9937-48. [PubMed: 21118965] [MGI Ref ID J:166963]
Tilli MT; Furth PA. 2003. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. Breast Cancer Res 5(4):202-5. [PubMed: 12817992] [MGI Ref ID J:84503]
Tran PT; Bendapudi PK; Lin HJ; Choi P; Koh S; Chen J; Horng G; Hughes NP; Schwartz LH; Miller VA; Kawashima T; Kitamura T; Paik D; Felsher DW. 2011. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med 3(103):103ra99. [PubMed: 21974937] [MGI Ref ID J:178317]
Tran PT; Shroff EH; Burns TF; Thiyagarajan S; Das ST; Zabuawala T; Chen J; Cho YJ; Luong R; Tamayo P; Salih T; Aziz K; Adam SJ; Vicent S; Nielsen CH; Withofs N; Sweet-Cordero A; Gambhir SS; Rudin CM; Felsher DW. 2012. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant kras-induced lung tumorigenesis. PLoS Genet 8(5):e1002650. [PubMed: 22654667] [MGI Ref ID J:185196]
Tran TP; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW. 2008. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS ONE 3(5):e2125. [PubMed: 18461184] [MGI Ref ID J:136212]
Varmus H; Pao W; Politi K; Podsypanina K; Du YC. 2005. Oncogenes come of age. Cold Spring Harb Symp Quant Biol 70:1-9. [PubMed: 16869733] [MGI Ref ID J:116747]
Vitale-Cross L; Amornphimoltham P; Fisher G; Molinolo AA; Gutkind JS. 2004. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 64(24):8804-7. [PubMed: 15604235] [MGI Ref ID J:94955]
Wang IC; Snyder J; Zhang Y; Lander J; Nakafuku Y; Lin J; Chen G; Kalin TV; Whitsett JA; Kalinichenko VV. 2012. Foxm1 mediates cross talk between Kras/mitogen-activated protein kinase and canonical Wnt pathways during development of respiratory epithelium. Mol Cell Biol 32(19):3838-50. [PubMed: 22826436] [MGI Ref ID J:188926]
Zeng X; Shaikh FY; Harrison MK; Adon AM; Trimboli AJ; Carroll KA; Sharma N; Timmers C; Chodosh LA; Leone G; Saavedra HI. 2010. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene 29(36):5103-12. [PubMed: 20581865] [MGI Ref ID J:169196]
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.Colony Maintenance
Breeding & Husbandry This strain originated on a FVB/N background and has been maintained on the same.
| Pricing for USA, Canada and Mexico shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2250.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Embryos
Price (US dollars $) Frozen Embryo $1600.00 Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryopreserved Embryos
Available to most shipping destinations1
This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.
1 Shipments cannot be made to Australia due to Australian government import restrictions.
2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2925.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Embryos
Price (US dollars $) Frozen Embryo $2080.00 Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryopreserved Embryos
Available to most shipping destinations1
This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.
1 Shipments cannot be made to Australia due to Australian government import restrictions.
2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
| Control | ||
|---|---|---|
| 001800 FVB/NJ | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.